United States Drugs for Metastatic Pancreatic Cancer Market Report 2016

November 2016 | 119 pages | ID: U7A81533DA8EN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Drugs for Metastatic Pancreatic Cancer

Revenue, means the sales value of Drugs for Metastatic Pancreatic Cancer

This report studies sales (consumption) of Drugs for Metastatic Pancreatic Cancer in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• AbbVie Inc.
• Aduro BioTech, Inc.
• ArQule, Inc.
• Array BioPharma Inc.
• AstraZeneca Plc
• Axcentua Pharmaceuticals AB
• Berg LLC
• Bionomics Limited
• Boehringer Ingelheim GmbH
• Boston Biomedical, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Clovis Oncology, Inc.
• Cornerstone Pharmaceuticals, Inc.
• CTI BioPharma Corp.
• CytRx Corporation
• Eleison Pharmaceuticals LLC
• Eli Lilly and Company
• Ensol Biosciences Inc.
• Erytech Pharma SA
• F. Hoffmann-La Roche Ltd.
• Fountain Biopharma Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Drugs Approved for Pancreatic Cancer
• Drugs under Development
• Type III

Split by applications, this report focuses on sales, market share and growth rate of Drugs for Metastatic Pancreatic Cancer in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

United States Drugs for Metastatic Pancreatic Cancer Market Report 2016

1 DRUGS FOR METASTATIC PANCREATIC CANCER OVERVIEW

1.1 Product Overview and Scope of Drugs for Metastatic Pancreatic Cancer
1.2 Classification of Drugs for Metastatic Pancreatic Cancer
  1.2.1 Drugs Approved for Pancreatic Cancer
  1.2.2 Drugs under Development
  1.2.3 Type III
1.3 Application of Drugs for Metastatic Pancreatic Cancer
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Drugs for Metastatic Pancreatic Cancer (2011-2021)
  1.4.1 United States Drugs for Metastatic Pancreatic Cancer Sales and Growth Rate (2011-2021)
  1.4.2 United States Drugs for Metastatic Pancreatic Cancer Revenue and Growth Rate (2011-2021)

2 UNITED STATES DRUGS FOR METASTATIC PANCREATIC CANCER COMPETITION BY MANUFACTURERS

2.1 United States Drugs for Metastatic Pancreatic Cancer Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Drugs for Metastatic Pancreatic Cancer Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Drugs for Metastatic Pancreatic Cancer Average Price by Manufactures (2015 and 2016)
2.4 Drugs for Metastatic Pancreatic Cancer Market Competitive Situation and Trends
  2.4.1 Drugs for Metastatic Pancreatic Cancer Market Concentration Rate
  2.4.2 Drugs for Metastatic Pancreatic Cancer Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES DRUGS FOR METASTATIC PANCREATIC CANCER SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Drugs for Metastatic Pancreatic Cancer Sales and Market Share by Type (2011-2016)
3.2 United States Drugs for Metastatic Pancreatic Cancer Revenue and Market Share by Type (2011-2016)
3.3 United States Drugs for Metastatic Pancreatic Cancer Price by Type (2011-2016)
3.4 United States Drugs for Metastatic Pancreatic Cancer Sales Growth Rate by Type (2011-2016)

4 UNITED STATES DRUGS FOR METASTATIC PANCREATIC CANCER SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Drugs for Metastatic Pancreatic Cancer Sales and Market Share by Application (2011-2016)
4.2 United States Drugs for Metastatic Pancreatic Cancer Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES DRUGS FOR METASTATIC PANCREATIC CANCER MANUFACTURERS PROFILES/ANALYSIS

5.1 AbbVie Inc.
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 AbbVie Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 Aduro BioTech, Inc.
  5.2.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 Aduro BioTech, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 ArQule, Inc.
  5.3.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 ArQule, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 Array BioPharma Inc.
  5.4.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 Array BioPharma Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 AstraZeneca Plc
  5.5.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 AstraZeneca Plc Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 Axcentua Pharmaceuticals AB
  5.6.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 Axcentua Pharmaceuticals AB Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Berg LLC
  5.7.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Berg LLC Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Bionomics Limited
  5.8.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Bionomics Limited Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 Boehringer Ingelheim GmbH
  5.9.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 Boehringer Ingelheim GmbH Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 Boston Biomedical, Inc.
  5.10.2 Drugs for Metastatic Pancreatic Cancer Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 Boston Biomedical, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview
5.11 Bristol-Myers Squibb Company
5.12 Celgene Corporation
5.13 Clovis Oncology, Inc.
5.14 Cornerstone Pharmaceuticals, Inc.
5.15 CTI BioPharma Corp.
5.16 CytRx Corporation
5.17 Eleison Pharmaceuticals LLC
5.18 Eli Lilly and Company
5.19 Ensol Biosciences Inc.
5.20 Erytech Pharma SA
5.21 F. Hoffmann-La Roche Ltd.
5.22 Fountain Biopharma Inc.
5.23 Gilead Sciences, Inc.
5.24 GlaxoSmithKline Plc

6 DRUGS FOR METASTATIC PANCREATIC CANCER MANUFACTURING COST ANALYSIS

6.1 Drugs for Metastatic Pancreatic Cancer Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Drugs for Metastatic Pancreatic Cancer

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Drugs for Metastatic Pancreatic Cancer Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Drugs for Metastatic Pancreatic Cancer Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES DRUGS FOR METASTATIC PANCREATIC CANCER MARKET FORECAST (2016-2021)

10.1 United States Drugs for Metastatic Pancreatic Cancer Sales, Revenue Forecast (2016-2021)
10.2 United States Drugs for Metastatic Pancreatic Cancer Sales Forecast by Type (2016-2021)
10.3 United States Drugs for Metastatic Pancreatic Cancer Sales Forecast by Application (2016-2021)
10.4 Drugs for Metastatic Pancreatic Cancer Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Disclosure Section
Research Methodology
Data Source
Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Drugs for Metastatic Pancreatic Cancer
Table Classification of Drugs for Metastatic Pancreatic Cancer
Figure United States Sales Market Share of Drugs for Metastatic Pancreatic Cancer by Type in 2015
Figure Drugs Approved for Pancreatic Cancer Picture
Figure Drugs under Development Picture
Table Application of Drugs for Metastatic Pancreatic Cancer
Figure United States Sales Market Share of Drugs for Metastatic Pancreatic Cancer by Application in 2015
Figure United States Drugs for Metastatic Pancreatic Cancer Sales and Growth Rate (2011-2021)
Figure United States Drugs for Metastatic Pancreatic Cancer Revenue and Growth Rate (2011-2021)
Table United States Drugs for Metastatic Pancreatic Cancer Sales of Key Manufacturers (2015 and 2016)
Table United States Drugs for Metastatic Pancreatic Cancer Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Drugs for Metastatic Pancreatic Cancer Sales Share by Manufacturers
Figure 2016 Drugs for Metastatic Pancreatic Cancer Sales Share by Manufacturers
Table United States Drugs for Metastatic Pancreatic Cancer Revenue by Manufacturers (2015 and 2016)
Table United States Drugs for Metastatic Pancreatic Cancer Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Drugs for Metastatic Pancreatic Cancer Revenue Share by Manufacturers
Table 2016 United States Drugs for Metastatic Pancreatic Cancer Revenue Share by Manufacturers
Table United States Market Drugs for Metastatic Pancreatic Cancer Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Drugs for Metastatic Pancreatic Cancer Average Price of Key Manufacturers in 2015
Figure Drugs for Metastatic Pancreatic Cancer Market Share of Top 3 Manufacturers
Figure Drugs for Metastatic Pancreatic Cancer Market Share of Top 5 Manufacturers
Table United States Drugs for Metastatic Pancreatic Cancer Sales by Type (2011-2016)
Table United States Drugs for Metastatic Pancreatic Cancer Sales Share by Type (2011-2016)
Figure United States Drugs for Metastatic Pancreatic Cancer Sales Market Share by Type in 2015
Table United States Drugs for Metastatic Pancreatic Cancer Revenue and Market Share by Type (2011-2016)
Table United States Drugs for Metastatic Pancreatic Cancer Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Drugs for Metastatic Pancreatic Cancer by Type (2011-2016)
Table United States Drugs for Metastatic Pancreatic Cancer Price by Type (2011-2016)
Figure United States Drugs for Metastatic Pancreatic Cancer Sales Growth Rate by Type (2011-2016)
Table United States Drugs for Metastatic Pancreatic Cancer Sales by Application (2011-2016)
Table United States Drugs for Metastatic Pancreatic Cancer Sales Market Share by Application (2011-2016)
Figure United States Drugs for Metastatic Pancreatic Cancer Sales Market Share by Application in 2015
Table United States Drugs for Metastatic Pancreatic Cancer Sales Growth Rate by Application (2011-2016)
Figure United States Drugs for Metastatic Pancreatic Cancer Sales Growth Rate by Application (2011-2016)
Table AbbVie Inc. Basic Information List
Table AbbVie Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Figure AbbVie Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Aduro BioTech, Inc. Basic Information List
Table Aduro BioTech, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Aduro BioTech, Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table ArQule, Inc. Basic Information List
Table ArQule, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table ArQule, Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Array BioPharma Inc. Basic Information List
Table Array BioPharma Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Array BioPharma Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table AstraZeneca Plc Basic Information List
Table AstraZeneca Plc Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table AstraZeneca Plc Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Axcentua Pharmaceuticals AB Basic Information List
Table Axcentua Pharmaceuticals AB Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Axcentua Pharmaceuticals AB Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Berg LLC Basic Information List
Table Berg LLC Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Berg LLC Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Bionomics Limited Basic Information List
Table Bionomics Limited Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Bionomics Limited Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Boehringer Ingelheim GmbH Basic Information List
Table Boehringer Ingelheim GmbH Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Boehringer Ingelheim GmbH Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Boston Biomedical, Inc. Basic Information List
Table Boston Biomedical, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Boston Biomedical, Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Bristol-Myers Squibb Company Basic Information List
Table Bristol-Myers Squibb Company Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Bristol-Myers Squibb Company Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Celgene Corporation Basic Information List
Table Celgene Corporation Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Celgene Corporation Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Clovis Oncology, Inc. Basic Information List
Table Clovis Oncology, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Clovis Oncology, Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Cornerstone Pharmaceuticals, Inc. Basic Information List
Table Cornerstone Pharmaceuticals, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Cornerstone Pharmaceuticals, Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table CTI BioPharma Corp. Basic Information List
Table CTI BioPharma Corp. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table CTI BioPharma Corp. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table CytRx Corporation Basic Information List
Table CytRx Corporation Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table CytRx Corporation Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Eleison Pharmaceuticals LLC Basic Information List
Table Eleison Pharmaceuticals LLC Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Eleison Pharmaceuticals LLC Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Eli Lilly and Company Basic Information List
Table Eli Lilly and Company Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Eli Lilly and Company Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Ensol Biosciences Inc. Basic Information List
Table Ensol Biosciences Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Ensol Biosciences Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Erytech Pharma SA Basic Information List
Table Erytech Pharma SA Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Erytech Pharma SA Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table F. Hoffmann-La Roche Ltd. Basic Information List
Table F. Hoffmann-La Roche Ltd. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table F. Hoffmann-La Roche Ltd. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Fountain Biopharma Inc. Basic Information List
Table Fountain Biopharma Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Fountain Biopharma Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Gilead Sciences, Inc. Basic Information List
Table Gilead Sciences, Inc. Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Gilead Sciences, Inc. Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table GlaxoSmithKline Plc Basic Information List
Table GlaxoSmithKline Plc Drugs for Metastatic Pancreatic Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table GlaxoSmithKline Plc Drugs for Metastatic Pancreatic Cancer Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Drugs for Metastatic Pancreatic Cancer
Figure Manufacturing Process Analysis of Drugs for Metastatic Pancreatic Cancer
Figure Drugs for Metastatic Pancreatic Cancer Industrial Chain Analysis
Table Raw Materials Sources of Drugs for Metastatic Pancreatic Cancer Major Manufacturers in 2015
Table Major Buyers of Drugs for Metastatic Pancreatic Cancer
Table Distributors/Traders List
Figure United States Drugs for Metastatic Pancreatic Cancer Production and Growth Rate Forecast (2016-2021)
Figure United States Drugs for Metastatic Pancreatic Cancer Revenue and Growth Rate Forecast (2016-2021)
Table United States Drugs for Metastatic Pancreatic Cancer Production Forecast by Type (2016-2021)
Table United States Drugs for Metastatic Pancreatic Cancer Consumption Forecast by Application (2016-2021)